TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07241390: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerot

Sponsor: Eli Lilly and Company · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 7140 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,361,704

Rescue Site Savings

+$7,495,896

Unlock Full NCT07241390 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07241390 Rescue Dossier →